Liminatus Pharma (NASDAQ:LIMN – Get Free Report) issued its earnings results on Friday. The company reported ($0.03) EPS for the quarter, FiscalAI reports.
Liminatus Pharma Price Performance
LIMN stock opened at $0.18 on Friday. The company has a 50 day simple moving average of $0.20 and a 200 day simple moving average of $0.61. The stock has a market cap of $8.08 million and a price-to-earnings ratio of -0.41. Liminatus Pharma has a 1 year low of $0.16 and a 1 year high of $33.66.
Analysts Set New Price Targets
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Liminatus Pharma in a research note on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Liminatus Pharma currently has a consensus rating of “Sell”.
Liminatus Pharma Company Profile
Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.
Read More
- Five stocks we like better than Liminatus Pharma
- Samsung Joins the $1 Trillion Club as AI Memory Demand Explodes
- Japan’s Stealth Bull Market: How U.S. Investors Can Get Exposure
- 3 Stocks to Own If Gas Prices Keep Rising
- 3 Crucial Aerospace Component Makers That Analysts Love
Receive News & Ratings for Liminatus Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liminatus Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
